Moderna, announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demon...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on smal...
ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Célere, a life sciences-focused consultancy i...
Cancer incidence is expected to rise significantly through 2050, particularly in lower-income countries, to 32 million new cases annually – a pot...
BIO International Convention 2024, The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Abu Dhabi...
Asensus Surgical, , a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger ...
Eisai Co., and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...
Investing in Global Health for a Safer Future World Health Organization's (WHO) "All for Health, Health for All: Investment Case 2025–2028...
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncol...
Syngene , a leading global contract research, development and manufacturing organization (CRDMO), announces the launch of its new protein production plat...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological p...
Thermo Fisher Scientific, a global leader in scientific research solutions, has introduced cutting-edge solutions aimed at enhancing research wor...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...
© 2025 Biopharma Boardroom. All Rights Reserved.
